264 related articles for article (PubMed ID: 27444306)
1. The Value of Medicines: A Crucial but Vague Concept.
Antoñanzas F; Terkola R; Postma M
Pharmacoeconomics; 2016 Dec; 34(12):1227-1239. PubMed ID: 27444306
[TBL] [Abstract][Full Text] [Related]
2. Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions-Report of the ISPOR Stated Preference Research Special Interest Group.
Marsh K; van Til JA; Molsen-David E; Juhnke C; Hawken N; Oehrlein EM; Choi YC; Duenas A; Greiner W; Haas K; Hiligsmann M; Hockley KS; Ivlev I; Liu F; Ostermann J; Poder T; Poon JL; Muehlbacher A
Value Health; 2020 Jul; 23(7):831-841. PubMed ID: 32762984
[TBL] [Abstract][Full Text] [Related]
3. Is there an alternative to quality-adjusted life years for supporting healthcare decision making?
Beresniak A; Dupont D
Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):351-7. PubMed ID: 27139424
[TBL] [Abstract][Full Text] [Related]
4. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
[TBL] [Abstract][Full Text] [Related]
5. Defining and Measuring the Affordability of New Medicines: A Systematic Review.
Antoñanzas F; Terkola R; Overton PM; Shalet N; Postma M
Pharmacoeconomics; 2017 Aug; 35(8):777-791. PubMed ID: 28477220
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Decision Makers' Constraints on the Outcome of Value of Information Analysis.
Koffijberg H; Knies S; Janssen MP
Value Health; 2018 Feb; 21(2):203-209. PubMed ID: 29477402
[TBL] [Abstract][Full Text] [Related]
7. Estimating the value of implementing reimbursement decisions: What can payers and manufacturers learn from economics?
Dixon S
Healthc Manage Forum; 2019 Nov; 32(6):303-306. PubMed ID: 31248283
[TBL] [Abstract][Full Text] [Related]
8. Managed Entry Agreements: Policy Analysis From the European Perspective.
Dabbous M; Chachoua L; Caban A; Toumi M
Value Health; 2020 Apr; 23(4):425-433. PubMed ID: 32327159
[TBL] [Abstract][Full Text] [Related]
9. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.
Panteli D; Eckhardt H; Nolting A; Busse R; Kulig M
Health Res Policy Syst; 2015 Sep; 13():39. PubMed ID: 26407728
[TBL] [Abstract][Full Text] [Related]
10. Health technology assessment in Brazil - an international perspective.
Lima SGG; Brito C; Andrade CJC
Cien Saude Colet; 2019 May; 24(5):1709-1722. PubMed ID: 31166506
[TBL] [Abstract][Full Text] [Related]
11. The changing role of economic evaluation in valuing medical technologies.
Rotter JS; Foerster D; Bridges JF
Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):711-23. PubMed ID: 23252354
[TBL] [Abstract][Full Text] [Related]
12. Are current ICER thresholds outdated? Valuing medicines in the era of personalized healthcare.
Carrera P; IJzerman MJ
Expert Rev Pharmacoecon Outcomes Res; 2016 Aug; 16(4):435-7. PubMed ID: 27118144
[No Abstract] [Full Text] [Related]
13. Impact of health technology assessment and managed entry schemes on reimbursement decisions of centrally authorised medicinal products in Belgium.
Van Wilder P; Pirson M; Dupont A
Eur J Clin Pharmacol; 2019 Jul; 75(7):895-900. PubMed ID: 30877328
[TBL] [Abstract][Full Text] [Related]
14. The value of innovation in decision-making in health care in Central Eastern Europe - The Sixth International Conference, 2 June 2017, Belgrade, Serbia.
Novakovic T; Martin AP; Parker M; Ferrario A; Vukovic S; Łanda K; Duba J; Dankó D; Kotsopoulos N; Godman B; Ristic J; Stefanovic D; Tesic D
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):519-521. PubMed ID: 28946800
[TBL] [Abstract][Full Text] [Related]
15. Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study.
Backhouse ME; Wonder M; Hornby E; Kilburg A; Drummond M; Mayer FK
Value Health; 2011 Jun; 14(4):608-15. PubMed ID: 21669387
[TBL] [Abstract][Full Text] [Related]
16. Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].
Lakdawalla DN; Doshi JA; Garrison LP; Phelps CE; Basu A; Danzon PM
Value Health; 2018 Feb; 21(2):131-139. PubMed ID: 29477390
[TBL] [Abstract][Full Text] [Related]
17. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].
Garrison LP; Neumann PJ; Willke RJ; Basu A; Danzon PM; Doshi JA; Drummond MF; Lakdawalla DN; Pauly MV; Phelps CE; Ramsey SD; Towse A; Weinstein MC
Value Health; 2018 Feb; 21(2):161-165. PubMed ID: 29477394
[TBL] [Abstract][Full Text] [Related]
18. The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe: issues, trends and recommendations.
Kolasa K; Kalo Z; Zah V
Expert Rev Pharmacoecon Outcomes Res; 2016 Aug; 16(4):483-8. PubMed ID: 27467881
[TBL] [Abstract][Full Text] [Related]
19. [Economic evaluation of healthcare technologies: an introduction for physicians].
Luengo-Fernández R; Hernández-Quesada C; Rivero-Arias O
Rev Neurol; 2011 Jul; 53(2):107-15. PubMed ID: 21720981
[TBL] [Abstract][Full Text] [Related]
20. 'Health Economics' and the evolution of economic evaluation of health technologies.
Hutton J
Health Econ; 2012 Jan; 21(1):13-8. PubMed ID: 22147623
[No Abstract] [Full Text] [Related]
[Next] [New Search]
